Kymab Limited

Medimmune Limited

Matthew John McCourt

Jamie Iain Campbell

Stephen John Arkinstall

Richard Charles Alfred Sainson

E-Chiang Lee

Ian Kirby

Miha Kosmac

Volker Germaschewski

Mohammed Hanif Ali

Stephen D Gillies

Hong Jin

Cassandra Van Krinks

Thomas Gallagher

Nikole Sandy

Xing Cheng

Danielle Carroll

Mark Galinski

Mihriban Tuna

Francisca Wollerton Van Horck

Cecilia Deantonio

Mustapha Faroudi

Joana De Abreu Carvalho

Ryan Fiehler

Frederick Akele

Fadi Badr

Nahida Parveen

Gwenoline Borhis

Rachael Jane Kimber

Robert Rowlands

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Anti-ICOS antibodies

Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.

Bispecific antibody for ICOS and PD-L1

The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.

Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo

Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia

Growing community of inventors

Cambridge, United Kingdom

Matthew John McCourt